NCCN Request for Proposals (RFP): Quality Improvement (QI) Project: Improving Metastatic Prostate Cancer (mPCa) Care Through Innovative Strategies
Funds quality improvement research to advance metastatic prostate cancer care by addressing disparities, improving provider practices, and expanding access to testing and therapies.
Funder: Pfizer Inc.
Due Dates: July 1, 2026 (Proposal submission deadline; 5:00 PM Eastern)
Funding Amounts: Total pool: $1 million; typical award: $200,000–$250,000 per project (up to 5 funded); max $250,000 per study (exceptions considered with justification).
Summary: Supports quality improvement projects to advance metastatic prostate cancer care by addressing disparities, improving provider practices, and expanding access to testing and therapies.
Key Information: U.S.-based institutions only; junior faculty encouraged; multi-institutional collaboration is prioritized.
Description
This grant opportunity, a collaboration between the National Comprehensive Cancer Network (NCCN) and Pfizer Global Medical Grants, seeks proposals for innovative, investigator-initiated quality improvement (QI) projects to enhance care delivery for patients with metastatic prostate cancer (mPCa). The focus is on developing scalable and sustainable interventions that address knowledge gaps, inefficiencies, and disparities in mPCa care. Priority areas include improving provider adherence to evidence-based testing and treatment, enhancing patient–provider communication and health literacy, optimizing toxicity mitigation strategies, and increasing the appropriate use of biomarker and genetic testing. Projects should aim to improve comprehensive care delivery, patient outcomes, and equity in access to therapies.
